Andrew Rawdin

BSc (Sheffield Hallam), MRes (York)

School of Medicine and Population Health

Health Economic Modeller

a.rawdin@sheffield.ac.uk
+44 114 222 0823
Regent Court (ScHARR)

Full contact details

Andrew Rawdin
School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Profile

I joined ScHARR in 2006 after gaining a BSc in Mathematics at Sheffield Hallam University and an MRes in Mathematics and Ecology at the University of York.

Research interests

My research interests are:

  • Discrete event simulation modelling
  • Health economic modelling
  • Development of a formal framework for the validation of computer simulation models in health economics
  • Economic modelling of Public Health interventions
  • Population dynamics modelling in epidemic disease transmission
  • Investigation of relationships between long term degenerative diseases and exposure to industrial pollutants.

I am currently working on the following projects:

  • Economic effectiveness of pharmaceutical interventions for hepatocellular carcinoma
  • The comparative economics effectiveness of different treatment methodologies for renal failure
Publications

Show: Featured publications All publications

Journal articles

  • Uttley L, Stevenson M, Scope A, Rawdin A & Sutton A (2015) . BMC Psychiatry, 15(1).
  • Uttley L, Stevenson M, Scope A, Rawdin A & Sutton A (2015) . BMC Psychiatry, 15.
  • Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J & Morgan MY (2015) . PharmacoEconomics.
  • Rawdin AC, Duenas A & Chilcott JB (2014) . Public Health, 128(9), 804-810.
  • Stevenson M, Gomersall T, Lloyd Jones M, Rawdin A, Hernández M, Dias S, Wilson D & Rees A (2014) . Health Technology Assessment, 18(17), 1-290.
  • Madan J, Rawdin A, Stevenson M & Tappenden P (2010) . Value in Health, 13(2), 215-221.
  • Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P & Wang J () . Health Technology Assessment, 18(16).
  • Tappenden P, Campbell F, Rawdin A, Wong R & Kalita N () . Health Technology Assessment, 16(20).
  • Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A () . Health Technology Assessment, 14(25).
  • Simpson E, Stevenson M, Rawdin A & Papaioannou D () . Health Technology Assessment, 13(2).

All publications

Journal articles

  • Kainz B, Heinrich MP, Makropoulos A, Oppenheimer J, Mandegaran R, Sankar S, Deane C, Mischkewitz S, Al-Noor F, Rawdin AC , Ruttloff A et al (2021) . npj Digital Medicine, 4.
  • Hock ES, Martyn-St James M, Wailoo A, Scott DL, Stevenson M, Rawdin A, Simpson EL, Dracup N & Young A (2021) . SN Comprehensive Clinical Medicine, 3(3), 838-854.
  • Floreskul V, Juma FZ, Daniel AB, Zamir I, Rawdin A, Stevenson M, Mughal Z & Padidela R (2020) . Frontiers in Public Health, 8.
  • Davis S, Simpson E, Hamilton J, James MM-S, Rawdin A, Wong R, Goka E, Gittoes N & Selby P (2020) . Health Technology Assessment, 24(29).
  • Ren S, Squires H, Hock E, Kaltenthaler E, Rawdin A & Alifrangis C (2019) . PharmacoEconomics, 37(9), 1073-1080.
  • Mukuria C, Rowen D, Harnan S, Rawdin A, Wong R, Ara R & Brazier J (2019) . Applied Health Economics and Health Policy, 17(3), 295-313.
  • Pandor A, Stevenson M, Stevens J, James MM-S, Hamilton J, Byrne J, Rudin C, Rawdin A & Wong R (2018) . Pharmacoeconomics, 36(8), 903-915.
  • Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A & Wong R (2018) . Pharmacoeconomics, 36(7), 759-768.
  • Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E, Wong R, Dracup N, Scott DL & Young A (2017) . Health Technology Assessment , 21(71), 1-258.
  • Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, Fischer A & Chilcott J (2017) . Journal of Epidemiology and Community Health, 71, 897-904.
  • Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F & Ghazavi M (2017) . PharmacoEconomics, 35(8), 805-815.
  • Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al (2016) . Health Technology Assessment, 20(78), 407-424.
  • Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al (2016) . Health Technology Assessment, 20(78), 1-406.
  • Uttley L, Stevenson M, Scope A, Rawdin A & Sutton A (2015) . BMC Psychiatry, 15(1).
  • Uttley L, Stevenson M, Scope A, Rawdin A & Sutton A (2015) . BMC Psychiatry, 15.
  • Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J & Morgan MY (2015) . PharmacoEconomics.
  • Uttley L, Scope A, Stevenson M, Rawdin A, Buck ET, Sutton A, Stevens J, Kaltenthaler E, Dent-Brown K & Wood C (2015) . Health Technology Assessment, 19(18).
  • Rawdin AC, Duenas A & Chilcott JB (2014) . Public Health, 128(9), 804-810.
  • Stevenson M, Gomersall T, Lloyd Jones M, Rawdin A, Hernández M, Dias S, Wilson D & Rees A (2014) . Health Technology Assessment, 18(17), 1-290.
  • Stevenson MD, Simpson EL, Rawdin AC & Papaioannou DE (2010) A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism.. J. Simulation, 4, 14-23.
  • Madan J, Rawdin A, Stevenson M & Tappenden P (2010) . Value in Health, 13(2), 215-221.
  • Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P & Wang J () . Health Technology Assessment, 18(16).
  • Tappenden P, Campbell F, Rawdin A, Wong R & Kalita N () . Health Technology Assessment, 16(20).
  • Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A () . Health Technology Assessment, 14(25).
  • Simpson E, Stevenson M, Rawdin A & Papaioannou D () . Health Technology Assessment, 13(2).

Conference proceedings

  • Stevenson M, Rawdin A, Uttley L & Sutton A (2014) . Value in Health, Vol. 17(7) (pp A458-A459)
  • Stevenson MD, Rawdin AC, Karnon JD & Brennan A (2008) Clopidogrel is cost-effective compared with aspirin in United Kingdom patients with a myocardial infarction who subsequently sustain an ischaemic stroke or peripheral arterial disease event. VALUE HEALTH, Vol. 11(3) (pp A194-A195)

Posters

  • Fotheringham J, Duenas A, Rawdin A, Wilkie M, Harrison B & Akehurst R Assessing the cost of parathyroidectomy as a treatment for uncontrolled secondary hyperparathyroidism in stage 5 chronic kidney disease.
  • Stevenson M, Rawdin A & Uttley L Cost effectiveness of group art therapy for patients with non-psychotic mental health disorders in England and Wales (2014).

Preprints

  • Kainz B, Makropoulos A, Oppenheimer J, Deane C, Mischkewitz S, Al-Noor F, Rawdin AC, Stevenson MD, Mandegaran R, Heinrich MP & Curry N (2021) , Cold Spring Harbor Laboratory.
  • Kainz B, Makropoulos A, Oppenheimer J, Deane C, Mischkewitz S, Al-Noor F, Rawdin AC, Stevenson MD, Heinrich‬ MP & Curry N () .
Teaching interests

My teaching interests are:

  • Supervising MSc dissertation projects
Professional activities and memberships

I am a member of the ScHARR Marketing Committee

Links